

NB: this is a summary translation of the press release original drafted in Japanese for the disclosure required in compliance with the TSE regulations.

December 10, 2020

Company Name: Asahi Intecc Co.,Ltd.
Representative: Masahiko Miyata, President & CEO
(Code: 7747, First section of Tokyo Stock Exchange
and Nagoya Stock Exchange)
Contact: Mizuho Ito, Member of Board & CFO,
General Manager of Administration

Company Name: Oncolys BioPharma Inc.
Representative: Yasuo Urata, President & CEO
(Code: 4588, Tokyo Stock Exchange Mothers)
Contact: Keiji Yoshimura, Director & Manager-
Accounting

Oncolys and ASAHI INTECC CO., LTD. Announces Conclusion of Capital and Business Alliance

Oncolys BioPharma (headquartered in Minato-ku, Tokyo; Yasuo Urata, Representative CEO; hereinafter “Oncolys”) is pleased to announce that today the board of the company resolved to enter into a capital and business alliance agreement with Asahi Intecc Co., Ltd. (headquartered in Seto-city, Aichi Prefecture; Masahiko Miyata, President & CEO ;hereinafter “Asahi Intecc”), one of the world’s leading medical device producer specialized in guide wires and catheter products, to continue to maintain and strengthen the mutually rewarding relationship which both companies have built up in the clinical settings through exchanges of information concerning development of efficient and better medical devices for easier and more precise administration of oncolytic viruses regardless of locations of the affected area, since 2015 to date, and to further pursue to accelerate the mutual growth in the field of oncology.

Through this reinforced relationship, Oncolys and Asahi Intecc will work together to address unmet medical needs in clinical settings, leveraging expertises of both companies, by strongly promoting development of medical devices which will enable more adequate and more precise administration of oncolytic viruses Oncolys has, for indications including esophageal cancer and other visceral/solid cancers which are commonly known to cause a significant deterioration of patients’ QOL.

The said capital tie-up will be formed through a third-party allotment and Oncolys will newly issue 118,600 common stocks which are equivalent to 0.83 % of total number of stocks issued by the company and worth approximately 2 million yen, and Asahi Intecc will accept all the stocks. Asahi Intecc intends to hold relevant stocks on a long term basis and it will report to Oncolys in writing, in pursuant to the terms and conditions of the agreement, should it decide to sell Oncolys stocks within two years from the payment due date of the agreement.

[Comments by Yasuo Urata, President & CEO, Oncolys BioPharma Inc.]

“Asahi Intecc is globally renowned for development, manufacturing and marketing of high-quality guide wires and guiding catheters for endovascular treatments. We believe Asahi Intecc has an outstanding technology which is indispensable for further advancing development of oncolytic virus immunotherapy in clinical settings as it will greatly contribute to make the administration of our oncolytic viruses to the affected area within a gastrointestinal tract much easier and more precise.”

[Comments by Masahiko Miyata, President & CEO of ASAHI INTECC Co., Ltd.]

“We believe that Oncolys’ oncolytic viral immunotherapy has a potential to become one of great breakthroughs in the oncology setting. We are confident that by combining it with our guide wires and guiding catheter technology, it will contribute to realize much easier access to the affected area which are usually deemed as difficult to reach or “almost inaccessible” for medication, and to give more cancer patients a chance to receive oncolytic virus immunotherapy treatment.”

###

Oncolys BioPharma Inc.	ASAHI INTECC CO., LTD.
Email: oncolys_information@oncolys.com	TEL: +81-561-48-5551
	Email: asahi-ir@asahi-intecc.com